Clinical Observation Of Kanglaite In The Treatment Of Primary Liver Cancer

Objective:To observe the clinical effect of intravenous infusion of kanglaite in alleviating adverse reactions after hepatic arterial chemoembolization(TACE)in patients with primary liver cancer and improving clinical symptoms and quality of life in patients with advanced liver cancer.Methods:A total of 60 patients who were diagnosed as primary liver cancer by clinical imaging and/or pathological examination in department of hepatobiliary and pancreatic medicine and department of radiological intervention in the second hospital of Jilin university were collected from September 2016 to September 2018.Forty patients eligible for TACE treatment were randomly divided into two groups.20 of the patients were treated with TACE combined with intravenous infusion of Kanglaite,namely,conventional supportive treatment was continued after TACE treatment,and meanwhile,sequential intravenous infusion of kanglaite injection [zhejiang kanglaite pharmaceutical co.,LTD.,national drug approval Z10970091,specification: 100ml:10g],200ml/ time and once a day.There were 20 patients who were treated with TACE alone,namely,conventional supportive treatment was continued after TACE treatment.In addition,20 patients with advanced primary liver cancer who did not comply with TACE treatment and other treatment methods were given intravenous infusion of Kanglaite injection 200ml/ time and once a day on the basis of conventional supportive treatment,which were included in the Kanglaite treatment group.Each group was treated for 21 days for a course of treatment.In the course of treatment,adverse reactions after treatment with TACE,including gastrointestinal symptoms(nausea and vomiting,abdominal pain,abdominal distension,loss of appetite),fever,bone marrow suppression(thrombocytopenia,and granulocytopenia),liver and kidney impairment(cereal third transaminase elevated,urea nitrogen increase)were observed in the combined treatment group and the TACE treatment group.One week after the end of the treatment,the tumor size and AFP level of the combined treatment group and the TACE treatment group were observed.After the course of treatment,the changes of clinical symptoms(abdominal distension,fatigue,appetite loss,nausea and vomiting,emaciation),degree of cancer pain,quality of life(measured by KPS score)and AFP level before and after treatment were observed in the Kanglaite treatment group.Results:1.Improvement of adverse reactions after TACE: at 1 week of treatment,the effective rates of nausea,vomiting,abdominal pain,fever and ALT elevation in the combined treatment group were 62.5%,52.9%,64.7% and 58.3%,respectively.The effective rates were significantly better than those in the TACE group alone(23.5%,16.7%,26.3%,15.4%),with statistically significant differences(P < 0.05).At 2 weeks of treatment,the effective rates of abdominal pain,anorexia and WBC in the combined treatment group were 82.4%,78.6% and 72.7%,while the effective rate was 38.9%,33.3% and 25.0% in TACE treatment group alone,and the difference was statistically significant(P < 0.05).2.The effective rate(CR+PR)and clinical benefit rate(CR+PR+SD)of tumor size change in the combined treatment group were 40.0% and 85.0%,respectively higher than the effective rate(CR+PR)and clinical benefit rate(CR+PR+SD)of the TACE treatment group,but the difference was not statistically significant(P > 0.05).The effective rate(CR+PR)of decreased AFP in the combined treatment group was 41.2%,which was better than that in the TACE treatment group alone(CR+PR)which was 22.2%,but the difference was not statistically significant(P > 0.05).The clinical benefit rate(CR+PR+SD)of decreased AFP in the combined treatment group was 82.4%,which was higher than that in the TACE treatment group(54.4%),and the difference was statistically significant(P < 0.05).3.The effective rate of Kangleite treatment group in alleviating the clinical symptoms of cancer pain,abdominal distension,fatigue,anorexia,nausea and vomiting,emaciation and other dyspepsia and improving the quality of life was 85.0%,94.4%,82.4%,89.5%,92.3%,73.3% and 55.0%,respectively.Clinical symptom scores and quality of life(KPS)were significantly improved before and after treatment,with statistically significant differences(P < 0.05).Conclusion:1.Kanglaite injection can alleviate adverse reactions of TACE treatment such as nausea and vomiting,abdominal pain,anorexia,fever,decreased WBC,elevated ALT,etc.and reduce AFP.The effect is better than that of TACE treatment alone.There was no significant difference in tumor volume reduction between the combined treatment group and the TACE treatment group.2.Kanglaite injection can alleviate the clinical symptoms including cancer pain,abdominal distension,fatigue,nausea and vomiting,appetite loss,weight loss and other dysentery in patients with advanced liver cancer,and improve the quality of life(KPS score)of patients at the same time.The curative effect is significant compared with before treatment,which is worthy of clinical promotion and application.